title: [Cycloferon efficacy of therapy of chronic hepatitis B (results of randomized multicentre study)].
abstract: The best therapeutic effect in the treatment of patients with chronic hepatitis B was observed with the use of cycloferon in the scheme of the antiviral therapy. The combination of cycloferon with lamivudine provided complete stable remission in 54.1% of the patients, whereas the use of a-interferon in combination with cycloferon provided remission in 44.1% of the lamivudine-resistant patients. The use of cycloferon in the therapy of chronic hepatitis B made it possible to lower the frequency and manifestation level of the side effects and prevented the lamivudine resistance development and generation of the virus mutants.
authors.forename: T V
authors.initials: TV
authors.lastname: Sologub
authors.forename: A A
authors.initials: AA
authors.lastname: Shul'diakov
authors.forename: L G
authors.initials: LG
authors.lastname: Goriacheva
authors.forename: I P
authors.initials: IP
authors.lastname: Baranova
authors.forename: Iu N
authors.initials: IuN
authors.lastname: Lin'kova
authors.forename: A L
authors.initials: AL
authors.lastname: Kovalenko
authors.forename: M G
authors.initials: MG
authors.lastname: Romantsov
mesh_terms: D000166:Acridines / Q000008:administration & dosage / Q000627:therapeutic use*; D000284:Administration, Oral; D000328:Adult; D004359:Drug Therapy, Combination; D006515:Hepatitis B virus; D019694:Hepatitis B, Chronic / Q000188:drug therapy*; D006801:Humans; D007273:Injections, Intramuscular; D007369:Interferon Inducers / Q000008:administration & dosage / Q000627:therapeutic use*; D019259:Lamivudine / Q000008:administration & dosage / Q000627:therapeutic use*; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D012426:Russia; D016896:Treatment Outcome
chemical_list: D000166:Acridines; D007369:Interferon Inducers; D018894:Reverse Transcriptase Inhibitors; D019259:Lamivudine; C026430:10-carboxymethyl-9-acridanone